keyword
MENU ▼
Read by QxMD icon Read
search

Bevacizumab

keyword
https://www.readbyqxmd.com/read/28634544/efficacy-of-subconjunctival-bevacizumab-injections-before-and-after-surgical-excision-in-preventing-pterygium-recurrence
#1
Raffaele Nuzzi, Federico Tridico
PURPOSE: To evaluate the efficacy of subconjunctival bevacizumab injections, before and after surgical excision with bare sclera technique, in preventing postoperative pterygium recurrence. MATERIAL AND METHODS: 83 eyes of 83 patients affected with primary pterygia underwent surgical excision. 42 eyes received two subconjunctival bevacizumab injections, at the dosage of 2.5 mg/0.1 ml, one week prior surgery and one week after intervention. Recurrence rate was evaluated among the two groups...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28634311/-bevacizumab-related-hyperintense-lesions-on-diffusion-weighted-imaging-at-different-locations-in-a-patient-with-malignant-glioma
#2
Shinya Oshiro, Naoki Wakuta, Shinichi Kawai, Koichi Miki, Yutaka Shigemori
We report the case of a 60-year-old man who first presented with transient difficulty of word recall. Subsequent MRI revealed an invasive brain tumor in the left frontal lobe. The patient underwent open biopsy, and diffuse astrocytoma(WHO grade II)was diagnosed. However, the malignant potential of this tumor was not particularly low because of a few enhancement on preoperative evaluation, and radiation therapy was initially performed. Four months after ending irradiation, temozolomide treatment was introduced for tumor regrowth...
June 2017: No Shinkei Geka. Neurological Surgery
https://www.readbyqxmd.com/read/28632865/effect-of-first-line-chemotherapy-combined-with-cetuximab-or-bevacizumab-on-overall-survival-in-patients-with-kras-wild-type-advanced-or-metastatic-colorectal-cancer-a-randomized-clinical-trial
#3
Alan P Venook, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Briant Fruth, Jeffrey A Meyerhardt, Deborah Schrag, Claire Greene, Bert H O'Neil, James Norman Atkins, Scott Berry, Blase N Polite, Eileen M O'Reilly, Richard M Goldberg, Howard S Hochster, Richard L Schilsky, Monica M Bertagnolli, Anthony B El-Khoueiry, Peter Watson, Al B Benson, Daniel L Mulkerin, Robert J Mayer, Charles Blanke
Importance: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic colorectal cancer, but the optimal choice of the initial biologic therapy in previously untreated patients is unknown. Objective: To determine if the addition of cetuximab vs bevacizumab to the combination of leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) regimen or the combination of leucovorin, fluorouracil, and irinotecan (FOLFIRI) regimen is superior as first-line therapy in advanced or metastatic KRAS wild-type (wt) colorectal cancer...
June 20, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28632850/cetuximab-or-bevacizumab-with-first-line-chemotherapy-in-advanced-kras-wild-type-colorectal-cancer-no-difference-but-not-the-same
#4
Christopher H Lieu, Wells A Messersmith
No abstract text is available yet for this article.
June 20, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28631775/-innovations-in-the-treatment-of-ovarian-cancer-analysis-of-the-therapeutic-development-from-platinum-to-immunotherapy
#5
Gesuino Angius, Pierangela Sepe, Anselmo Papa, Silverio Tomao, Federica Tomao
Ovarian cancer is the seventh most common cancer in women. The therapeutic approach provides for an appropriate integration between surgery and chemotherapy. Surgery is an important step for diagnosis, staging and therapy, aiming at the complete cytoreduction of all macroscopic visible disease. At the moment, adjuvant and first-line chemotherapy has as a standard the carboplatin-paclitaxel combination. Further, the addition of bevacizumab in the advanced stage (IIIB-IV) is strongly recommended. Despite the initial effectiveness, however, 70-80% of patients develop relapsed disease within the first two years and require subsequent treatment lines that have palliative, rather than curative purposes and that seek to reach a chronic state for the disease...
June 2017: Recenti Progressi in Medicina
https://www.readbyqxmd.com/read/28631382/a-phase-ii-trial-evaluating-the-feasibility-of-adding-bevacizumab-to-standard-osteosarcoma-therapy
#6
Fariba Navid, Victor M Santana, Michael Neel, M Beth McCarville, Barry L Shulkin, Jianrong Wu, Catherine A Billups, Shenghua Mao, Vinay M Daryani, Clinton F Stewart, Michelle Kunkel, Wendene Smith, Deborah Ward, Alberto S Pappo, Armita Bahrami, David M Loeb, Jennifer Reikes Willert, Bhaskar N Rao, Najat C Daw
Increased vascular endothelial growth factor (VEGF) expression in osteosarcoma correlates with a poor outcome. We conducted a phase II trial to evaluate the feasibility and efficacy of combining bevacizumab, a monoclonal antibody against VEGF, with methotrexate, doxorubicin and cisplatin (MAP) in patients with localized osteosarcoma. Eligible patients received 2 courses of MAP chemotherapy before definitive surgery at week 10. Bevacizumab (15 mg/kg) was administered 3 days before starting chemotherapy then on day 1 of weeks 3 and 5 of chemotherapy...
June 20, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28631191/effect-of-angiotensin-system-inhibitors-on-survival-in-newly-diagnosed-glioma-patients-and-recurrent-glioblastoma-patients-receiving-chemotherapy-and-or-bevacizumab
#7
Victor A Levin, James Chan, Meenal Datta, Jennie L Yee, Rakesh K Jain
Given prior studies that suggest the use of angiotensin system inhibitors (ASIs) is associated with prolonged overall survival (OS) in glioblastoma (GBM) patients, we evaluated the effect of ASIs in glioma patients receiving chemotherapy and/or bevacizumab (BEV). Using retrospective IRB-approved electronic chart review of newly diagnosed WHO grade 2-4 glioma patients from the Kaiser Permanente Tumor Registry of Northern California, we evaluated the impact of ASIs on OS by Cox proportional hazard model analysis for subgroups who received cytotoxic therapy, cytotoxic therapy with BEV, or BEV alone, as well as those with recurrent GBM (rGBM)...
June 19, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28630789/efficacy-of-intravitreal-bevacizumab-in-treatment-of-proliferative-type-2-idiopathic-juxtafoveal-telangiectasia
#8
Ökkeş Baz, İhsan Yılmaz, Cengiz Alagöz, Ali Demircan, İrfan Perente, Abdullah Özkaya, Muhittin Taşkapılı
OBJECTIVES: To evaluate the effectiveness of intravitreal bevacizumab (IVB) in patients with subretinal neovascularization secondary to type 2 juxtafoveal telangiectasia. MATERIALS AND METHODS: Ten eyes of 10 patients were included in this retrospective study. All cases were treated with IVB (1.25 mg bevacizumab). Visual acuity and slit-lamp anterior and posterior segment examinations were performed at each visit. Central macular thickness (CMT) and intraretinal/subretinal fluid were evaluated via spectral domain optical coherence tomography (OCT)...
June 2017: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/28630787/evaluation-of-aflibercept-treatment-responses-in-eyes-with-bevacizumab-ranibizumab-resistant-wet-age-related-macular-degeneration
#9
Tuncay Topal, Taner Kar, Yıldıray Yıldırım, Sercan Koray Sağdıç, Cihan Büyükavşar, Abdullah Kaya, Ali Ayata, Murat Sönmez, Melih Hamdi Ünal
OBJECTIVES: To evaluate anatomic and functional results after switching from intravitreal bevacizumab or ranibizumab treatment to aflibercept for wet (neovascular) age-related macular degeneration. MATERIALS AND METHODS: This retrospective study included 22 eyes of 22 patients resistant to treatment with at least 6 injections of bevacizumab or ranibizumab. The first three injections had been applied monthly, the others pro re nata (PRN). Outcome measures were follow-up period, injection number, best corrected visual acuity (BCVA), central retinal thickness (CRT) and pigment epithelial detachment (PED) height...
June 2017: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/28629461/cost-effectiveness-of-lung-cancer-screening-and-treatment-methods-a-systematic-review-of-systematic-reviews
#10
Farbod Ebadifard Azar, Saber Azami-Aghdash, Fatemeh Pournaghi-Azar, Alireza Mazdaki, Aziz Rezapour, Parvin Ebrahimi, Negar Yousefzadeh
BACKGROUND: Due to extensive literature in the field of lung cancer and their heterogeneous results, the aim of this study was to systematically review of systematic reviews studies which reviewed the cost-effectiveness of various lung cancer screening and treatment methods. METHODS: In this systematic review of systematic reviews study, required data were collected searching the following key words which selected from Mesh: "lung cancer", "lung oncology", "lung Carcinoma", "lung neoplasm", "lung tumors", "cost- effectiveness", "systematic review" and "Meta-analysis"...
June 19, 2017: BMC Health Services Research
https://www.readbyqxmd.com/read/28629380/retinal-and-vitreous-metastases-from-hepatocholangiocarcinoma
#11
Anna Praidou, Sarita Jacob, Luciane Irion, Ramesh Sivaraj, Carl Groenewald, Sarah E Coupland, Heinrich Heimann
BACKGROUND: To report a case of metastatic hepatocholangiocarcinoma to the vitreous and retina. CASE PRESENTATION: A 70-year-old male, who was recently diagnosed with hepatocholangiocarcinoma, was complaining of floaters in his right eye over the past 5 months and was referred to the Liverpool Ocular Oncology Centre. On presentation, his visual acuity in the right eye was 6/24. Fundus exam revealed a whitish, unilateral, full-thickness retinal lesion at the inferotemporal arcade of his right eye, with vitreous infiltration and subretinal fluid...
June 19, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28627960/lack-of-functional-normalisation-of-tumour-vessels-following-anti-angiogenic-therapy-in-glioblastoma
#12
Nina Obad, Heidi Espedal, Radovan Jirik, Per Oystein Sakariassen, Cecilie Brekke Rygh, Morten Lund-Johansen, Torfinn Taxt, Simone P Niclou, Rolf Bjerkvig, Olivier Keunen
Neo-angiogenesis represents an important factor for the delivery of oxygen and nutrients to a growing tumour, and is considered to be one of the main pathodiagnostic features of glioblastomas (GBM). Anti-angiogenic therapy by vascular endothelial growth factor (VEGF) blocking agents has been shown to lead to morphological vascular normalisation resulting in a reduction of contrast enhancement as seen by magnetic resonance imaging (MRI). Yet the functional consequences of this normalisation and its potential for improved delivery of cytotoxic agents to the tumour are not known...
January 1, 2017: Journal of Cerebral Blood Flow and Metabolism
https://www.readbyqxmd.com/read/28627678/bevacizumab-counteracts-vegf-dependent-resistance-to-erlotinib-in-an-egfr-mutated-nsclc-xenograft-model
#13
Chinami Masuda, Mieko Yanagisawa, Keigo Yorozu, Mitsue Kurasawa, Koh Furugaki, Nobuyuki Ishikura, Toshiki Iwai, Masamichi Sugimoto, Kaname Yamamoto
Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), shows superior efficacy in patients with non-small cell lung cancer (NSCLC) harboring activating EGFR mutations (EGFR Mut+). However, almost all tumors eventually develop resistance to erlotinib. Recently, the Phase II JO25567 study reported significant prolongation of progression-free survival (PFS) by erlotinib plus bevacizumab combination compared with erlotinib in EGFR Mut+ NSCLC. Herein, we established a preclinical model which became refractory to erlotinib after long-term administration and elucidated the mode of action of this combination...
June 8, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/28626816/evaluation-of-topical-bevacizumab-as-an-adjunct-to-mitomycin-c-augmented-trabeculectomy
#14
Reza Zarei, Masoumeh Masoumpour, Sasan Moghimi, Ghasem Fakhraei, Yadollah Eslami, Masoud Mohammadi
PURPOSE: To investigate the safety and synergistic effect of topical bevacizumab after trabeculectomy surgery with mitomycin C (MMC). METHODS: In this prospective, non-randomized, comparative interventional study, 40 eyes from 40 patients with uncontrolled open-angle glaucoma were studied after they underwent primary trabeculectomy with mitomycin C (0.02% for 2 min). Following the procedure topical bevacizumab (4 mg/mL) was used for 2 weeks 4 times daily in group A...
June 2017: Journal of Current Ophthalmology
https://www.readbyqxmd.com/read/28626398/esophageal-metastasis-from-rectal-cancer-successfully-treated-with-fluorouracil-based-chemotherapy-with-bevacizumab-a-case-report-and-review-of-the-literature
#15
Sho Watanabe, Atsuo Takashima, Hirokazu Taniguchi, Yusaku Tanaka, Shoko Nakamura, Natsuko Okita, Yoshitaka Honma, Satoru Iwasa, Ken Kato, Tetsuya Hamaguchi, Narikazu Boku
Esophageal metastasis from colorectal carcinoma is uncommon, and diagnosis of esophageal metastasis is difficult. We report a case of a 54-year-old woman with postoperative recurrence of rectal cancer metastasizing to the esophagus. She underwent rectectomy and adjuvant chemotherapy with fluorouracil, leucovorin plus oxaliplatin for stage IIIB rectal cancer. Three years later, she presented with dysphagia and cough. Computed tomography showed thickening of the esophagus wall, enlargement of the lymph nodes in the mediastinum and abdomen, and ground-glass opacities in the right lung...
May 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28626375/intravenous-bevacizumab-therapy-in-a-patient-with-hereditary-hemorrhagic-telangiectasia-eng-e137k-alcoholic-cirrhosis-and-portal-hypertension
#16
Luigi F Bertoli, Pauline L Lee, Lauren Lallone, James C Barton
Intravenous bevacizumab decreased mucosal bleeding in some patients with hereditary hemorrhagic telangiectasia (HHT). We treated a 47-year-old male who had HHT, severe epistaxis, and gastrointestinal bleeding, alcoholic cirrhosis, and portal hypertension with intravenous bevacizumab 2.5 mg/kg every 2 weeks. We tabulated these measures weekly during weeks 1-33 (no bevacizumab); 34-57 (bevacizumab); and 58-97 (no bevacizumab): hemoglobin (Hb) levels; platelet counts; units of transfused packed erythrocytes (PRBC units); and quantities of iron infused as iron dextran to support erythropoiesis...
May 2017: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/28626084/optimization-of-ras-braf-mutational-analysis-confirms-improvement-in-patient-selection-for-clinical-benefit-to-anti-egfr-treatment-in-metastatic-colorectal-cancer
#17
Cristina Santos, Daniel Azuara, Rocio Garcia-Carbonero, Pilar García Alfonso, Alfredo Carrato, Elena Elez, Auxiliadora Gómez, Ferran Losa, Clara Montagut, Bartomeu Massuti, Valenti Navarro, Mar Varela, Adriana López-Doriga, Victor Moreno, Manuel Valladares, Jose Luis Manzano, José Maria Viéitez, Enrique Aranda, Xavier Sanjuan, Josep Tabernero, Gabriel Capella, Ramon Salazar
In metastatic colorectal cancer (mCRC) recent studies have shown the importance to accurately quantify low-abundance mutations of RAS pathway because anti-EGFR therapy may depend on certain mutation thresholds. We aimed to evaluate the added predictive value of extended RAS panel testing using two commercial assays and a highly sensitive and quantitative digital PCR (dPCR). Tumor samples from 583 mCRC patients treated with anti-EGFR (n=255) or bevacizumab (n=328) based therapies from several clinical trials and retrospective series from the TTD/RTICC Spanish network were analyzed by cobas®, therascreen® and dPCR...
June 16, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28625650/switch-maintenance-chemotherapy-using-s-1-with-or-without-bevacizumab-in-patients-with-advanced-non-small-cell-lung-cancer-a-phase-ii-study
#18
Seiji Niho, Yuichiro Ohe, Hironobu Ohmatsu, Shigeki Umemura, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto
OBJECTIVES: We conducted this single-institute; prospective, non-randomized parallel two-arm phase II study to evaluate the efficacy and safety of switch maintenance chemotherapy with S-1 after induction therapy with a platinum-based regimen in patients with advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients not showing disease progression after induction platinum-based chemotherapy received S-1 at the dose of 40mg/m(2) twice daily for 14 consecutive days, every three weeks, with or without bevacizumab (Bev) at the dose of 15mg/kg...
June 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28625315/cancer-de-l%C3%A2-ovaire-prise-en-charge-pluridisciplinaire-du-cancer-de-l%C3%A2-ovaire-en-premi%C3%A3-re-ligne-recommandations-saint-paul-de-vence-2016
#19
Jean-Marc Classe, Frédéric Guyon, Claire Falandry, Mojgan Devouassoux-Shisheboran, Frédéric Selle, Florence Joly
Recommendations for the clinical practice of Nice-Saint-Paul de Vence The treatment of advanced epithelial ovarian cancer is multidisciplinary involving surgical teams and surgery and medical oncology, experienced in the management of this disease, following published quality criteria. The strategy must be validated in multidisciplinary consultation meeting (RCP) before any treatment. The pre-therapeutic assessment includes the histological diagnosis, evaluation of the tumor extension (biological assessment, markers, imaging, laparoscopy), assessment of the general state (operability), in order to answer the question of feasibility of an initial optimal surgery...
May 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/28625314/prise-en-charge-du-cancer-du-col-de-l%C3%A2-ut%C3%A3-rus-m%C3%A3-tastatique-et-ou-en-rechute
#20
Jean-Emmanuel Kurtz, Véronique D'Hondt, Fabrice Lécuru, Catherine Lhommé
The prognosis of metastatic or recurrent cervical cancer remains dismal. The poor chemosensitivity of this tumor- is an issue, especially in case of recurrence in irradiated fields. Still, chemotherapy has shown some efficacy, and mostly consists in platinum-based doublets. The addition of bevacizumab to chemotherapy has been recently validated. However, most of these patients present with complex clinical situations and the treatment strategy has to be discussed in multidisciplinary tumor boards.
May 2017: Bulletin du Cancer
keyword
keyword
1763
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"